Search Results - "Nichakawade, Tushar D"

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers by Nichakawade, Tushar D., Ge, Jiaxin, Mog, Brian J., Lee, Bum Seok, Pearlman, Alexander H., Hwang, Michael S., DiNapoli, Sarah R., Wyhs, Nicolas, Marcou, Nikita, Glavaris, Stephanie, Konig, Maximilian F., Gabelli, Sandra B., Watson, Evangeline, Sterling, Cole, Wagner-Johnston, Nina, Rozati, Sima, Swinnen, Lode, Fuchs, Ephraim, Pardoll, Drew M., Gabrielson, Kathy, Papadopoulos, Nickolas, Bettegowda, Chetan, Kinzler, Kenneth W., Zhou, Shibin, Sur, Surojit, Vogelstein, Bert, Paul, Suman

“…Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies 1 –…”
Get full text

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities by Mog, Brian J, Marcou, Nikita, DiNapoli, Sarah R, Pearlman, Alexander H, Nichakawade, Tushar D, Hwang, Michael S, Douglass, Jacqueline, Hsiue, Emily Han-Chung, Glavaris, Stephanie, Wright, Katharine M, Konig, Maximilian F, Paul, Suman, Wyhs, Nicolas, Ge, Jiaxin, Miller, Michelle S, Azurmendi, P, Watson, Evangeline, Pardoll, Drew M, Gabelli, Sandra B, Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

“…Two types of engineered T cells have been successfully used to treat patients with cancer, one with an antigen recognition domain derived from antibodies…”
Get more information

Abstract LB095: Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen by Mog, Brian J., DiNapoli, Sarah R., Hwang, Michael S., Nichakawade, Tushar D., Douglass, Jacqueline, Hsiue, Emily Han-Chung, Wright, Katharine M., Pearlman, Alexander H., Konig, Maximilian F., Paul, Suman, Wyhs, Nicolas, Marcou, Nikita, Glavaris, Stephanie, Ge, Jiaxin, Miller, Michelle S., Azurmendi, P. Aitana, Watson, Evangeline, Pardoll, Drew M., Gabelli, Sandra B., Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Zhou, Shibin

“…Mutation-associated neoantigens (MANAs) are exquisitely cancer-specific therapeutic targets. However, MANAs are present at ultra-low densities on the cancer…”
Get full text